(firstQuint)Dasotraline Pediatric Extension Study.

 This is an open-label, flexibly-dosed, 26 week extension study in children and adolescents with ADHD who have completed 6 weeks of double-blind treatment in the core study (SEP360 202).

 This study will evaluate the long-term safety and tolerability of dasotraline in this population.

.

 Dasotraline Pediatric Extension Study@highlight

This is an open label 26 week extension study for subjects who completed SEP360-202.

